Bioxytran, Inc. (OTCMKTS:BIXT – Get Free Report) shares traded up 3.1% during trading on Friday . The stock traded as high as $0.15 and last traded at $0.13. 288,748 shares changed hands during trading, an increase of 189% from the average session volume of 99,998 shares. The stock had previously closed at $0.13.
Bioxytran Stock Performance
The stock has a market cap of $23.05 million, a PE ratio of -3.31 and a beta of -0.83. The firm has a fifty day moving average price of $0.12 and a 200 day moving average price of $0.13.
Bioxytran (OTCMKTS:BIXT – Get Free Report) last released its quarterly earnings data on Friday, March 22nd. The company reported ($0.01) earnings per share for the quarter.
About Bioxytran
Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.
Further Reading
- Five stocks we like better than Bioxytran
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Comprehensive Analysis of PayPal Stock
- Investing in Travel Stocks Benefits
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- The Role Economic Reports Play in a Successful Investment Strategy
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.
